Gerresheimer Shares Rocket on Debt Deal and Divestment Drive

Gerresheimer shares surge 21% as creditors grant major deadline extensions and the company pursues a strategic US divestment, easing investor concerns over its accounting crisis.

Shares in German pharmaceutical packaging specialist Gerresheimer AG surged 21 percent over the past week, closing at EUR 20.82. This dramatic rally defies the typical market reaction to delayed financial reports and a recent expulsion from Germany's SDAX index, instead highlighting investor relief over two critical developments.

The company has secured a vital reprieve from its creditors. Holders of EUR 870 million in Schuldschein loans, representing a 96 percent majority, agreed to extend the deadline for submitting the audited 2025 annual report until the end of September 2026. Concurrently, its banking partners have suspended key covenant tests related to leverage ratios until the third quarter of 2026. This comprehensive agreement provides the management team, led by CFO Wolf Lehmann, with the necessary breathing room to resolve its accounting issues.

Operationally, the business continues to perform. Management confirms that development in the current fiscal year is meeting internal expectations, driven by robust demand for specialized packaging from the pharma and biotech sectors. Analyst James Vane-Tempest of Jefferies notes the company's core operational health remains entirely intact, despite the administrative challenges at its Düsseldorf headquarters.

A parallel strategic move is adding to the positive sentiment. Gerresheimer is actively pursuing the sale of its US subsidiary, Centor. The process, managed by investment bank Morgan Stanley, is reportedly on track, with a double-digit number of interested parties already engaged. The board aims to conclude the transaction within the current calendar year. Analyst Delphine Le Louet from Bernstein views this decisive divestment strategy as a significant relief for investors, with the proceeds expected to substantially strengthen the group's balance sheet.

The current crisis stems from an external audit investigating business transactions from the past two years. Germany's audit oversight body, APAS, has opened an investigation into auditor KPMG over allegations of systematic errors in revenue recognition. These persistent delays cost Gerresheimer its place in the SDAX in April.

As part of its broader restructuring, the company expects to book non-cash impairment charges of up to EUR 240 million for 2025. It will also shutter its Chicago glass plant by the end of 2026, shifting production to existing facilities in Italy and India.

Despite the extended creditor deadlines, management insists on an ambitious internal timeline. The key milestone remains June 2026, when the company still plans to publish the audited annual report. To ensure a consistent data basis, it has postponed the release of its Q1 2026 figures and its annual general meeting. The stock's current price sits nearly 34 percent above its 52-week low, suggesting a floor may be forming.

Looking ahead, provided operational stability holds, the group intends to focus on lucrative biopharma packaging, including products for weight-loss medications, once its financial reporting is back on track.